Last reviewed · How we verify
R-miniCHOP
R-miniCHOP is a reduced-intensity chemotherapy regimen combining rituximab with a modified CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) backbone designed to treat lymphomas with lower toxicity.
R-miniCHOP is a reduced-intensity chemotherapy regimen combining rituximab with a modified CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) backbone designed to treat lymphomas with lower toxicity. Used for B-cell non-Hodgkin lymphoma in elderly or frail patients.
At a glance
| Generic name | R-miniCHOP |
|---|---|
| Sponsor | Universität des Saarlandes |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
R-miniCHOP reduces the doses of conventional CHOP chemotherapy agents while maintaining the anti-CD20 monoclonal antibody rituximab, aiming to preserve efficacy against B-cell lymphomas while decreasing treatment-related morbidity and mortality. This approach is particularly relevant for elderly or frail patients who may not tolerate standard-dose R-CHOP.
Approved indications
- B-cell non-Hodgkin lymphoma in elderly or frail patients
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Infection
- Nausea/vomiting
- Cardiotoxicity
Key clinical trials
- Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (PHASE2, PHASE3)
- Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older (PHASE2)
- Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (PHASE3)
- The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years (PHASE3)
- Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients (NA)
- Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy (PHASE3)
- Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ (PHASE3)
- Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-miniCHOP CI brief — competitive landscape report
- R-miniCHOP updates RSS · CI watch RSS
- Universität des Saarlandes portfolio CI